For a patient with a diagnosed deep‑vein thrombosis (DVT), how long should they remain on Eliquis (apixaban)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Duration of Eliquis (Apixaban) for DVT Treatment

For a patient with diagnosed DVT, the duration of Eliquis depends critically on whether the DVT was provoked or unprovoked, with initial treatment lasting at least 3 months, followed by extended therapy decisions based on bleeding risk and recurrence risk.

Initial Treatment Phase

All patients with proximal DVT require at least 3 months of anticoagulation 1. The FDA-approved Eliquis regimen is 2:

  • 10 mg twice daily for 7 days
  • Then 5 mg twice daily for the remainder of treatment

For isolated distal (calf) DVT, 3 months is sufficient and extended therapy is not recommended 3.

Decision Point at 3 Months: Provoked vs. Unprovoked

Provoked DVT (Surgery or Transient Risk Factor)

Stop anticoagulation at 3 months 1. This is a strong recommendation because:

  • Surgery-provoked DVT has annual recurrence risk <1% after stopping 3
  • The guidelines explicitly recommend 3 months over extended therapy for provoked events 1

Exception: For hormone-associated DVT in women who stop hormonal therapy, 3 months is sufficient 3.

Unprovoked Proximal DVT

Consider extended (indefinite) anticoagulation beyond 3 months 3. The decision algorithm:

  1. Low or moderate bleeding risk: Suggest extended therapy 1

    • Unprovoked DVT carries >5% annual recurrence risk 3
    • This exceeds typical anticoagulation bleeding risk
  2. High bleeding risk: Stop at 3 months 1

  3. If continuing beyond 3 months: Switch to Eliquis 2.5 mg twice daily after completing at least 6 months of treatment 2

    • The AMPLIFY-EXT trial demonstrated this reduced dose effectively prevents recurrence with lower bleeding rates 2
    • This dose is specifically FDA-approved for "reduction in risk of recurrence of DVT and PE" 2

Extended Therapy Monitoring

Reassess continuation annually 1. At each assessment, re-evaluate:

  • Bleeding risk changes
  • Patient preference
  • Ongoing cancer or other acquired risk factors

Special Populations

Cancer-Associated DVT

Continue anticoagulation as long as cancer is active or under treatment 1, 4. While LMWH is preferred initially 1, recent evidence suggests apixaban 2.5 mg twice daily may be effective for extended therapy in cancer patients 5.

Recurrent Unprovoked DVT

Indefinite anticoagulation is strongly recommended 4. These patients have demonstrated high thrombotic risk.

Common Pitfalls

  • Don't use 5 mg twice daily for extended therapy: The FDA label and trials support 2.5 mg twice daily after initial treatment 2
  • Don't forget the 3-month minimum: Even provoked DVT requires full initial treatment 1
  • Don't continue indefinitely without reassessment: Annual review is essential 1
  • Distinguish proximal from distal DVT: Isolated calf DVT has different recurrence risk and doesn't warrant extended therapy 3

The strongest predictor of recurrence is whether the DVT was provoked or unprovoked 3. This single factor should drive your decision at the 3-month mark more than any other consideration.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.